Vascular endothelial growth factor-121 localised protein delivery - GenVec

Drug Profile

Vascular endothelial growth factor-121 localised protein delivery - GenVec

Alternative Names: AdGVVEGF121.10NH; BIOBYPASS; BIOBYPASS® angiogen; BIOBYPASS®-CAD; CI 1023; Vascular endothelial growth factor gene therapy - GenVec

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GenVec
  • Developer Cordis Corporation; GenVec
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Ischaemic heart disorders
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
  • 04 Oct 2015 Cordis Corporation has been acquired by Cardinal Health
  • 14 Mar 2005 Phase-II clinical trials in Ischaemic heart disorders in Europe (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top